Opetarl

Opetarl may be available in the countries listed below.

Ingredient matches for Opetarl

Cilostazol

Cilostazol is reported as an ingredient of Opetarl in the following countries:

• Japan

International Drug Name Search

betaine

BEE-ta-een

Commonly used brand name(s)

In the U.S.

• Cystadane

Available Dosage Forms:

• Powder for Suspension


• Tablet

Therapeutic Class: Digestant

Uses For betaine

Betaine is used to treat a lack of or defect in certain enzymes that causes too much homocysteine in the blood and urine. betaine removes the extra homocysteine from the body.

betaine is available only with your doctor's prescription.

Before Using betaine

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For betaine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to betaine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

betaine has been tested in children and, in effective doses, has not been shown to cause different side effects or problems than it does in adults. However, children may require more frequent changes in their dose than adults.

Geriatric

Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing the use of betaine in the elderly with use in other age groups.

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	C	Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Proper Use of betaine

Betaine powder should be mixed with 4 to 6 ounces of juice, milk, or water until completely dissolved. The solution should be used immediately after mixing.

Do not use if the powder does not dissolve completely or gives a colored solution.

Betaine should be taken with meals.

It is important that you follow any special instructions from your doctor, such as taking folic acid, pyridoxine (vitamin B 6), and vitamin B 12 supplements. If you have any questions about this, check with your doctor.

Dosing

The dose of betaine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of betaine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For oral dosage form (powder for solution):
  
  • To prevent buildup of homocysteine:
    
    • Adults, teenagers, and children 3 years of age and older—The starting dose is usually 3 grams taken two times a day with meals. Your doctor may adjust your dose as needed.
    
    
    • Children younger than 3 years of age—The dose is based on body weight and must be determined by your doctor. Betaine should be taken with meals.
    
    
  
  

Missed Dose

If you miss a dose of betaine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Precautions While Using betaine

Your doctor should check your progress at regular visits to make sure that betaine is working properly.

betaine Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

• Diarrhea


• nausea


• stomach upset

Betaine may cause a body odor. Other side effects not listed above may also occur in some patients. If you notice any other effects, check with your doctor.

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More betaine resources

• Betaine Side Effects (in more detail)
• Betaine Use in Pregnancy & Breastfeeding
• Betaine Support Group
• 0 Reviews for Betaine - Add your own review/rating

• betaine Concise Consumer Information (Cerner Multum)


• Betaine Powder MedFacts Consumer Leaflet (Wolters Kluwer)


• Cystadane Prescribing Information (FDA)

Compare betaine with other medications

• Nonalcoholic Fatty Liver Disease

Sutent

Sutent is a brand name of sunitinib, approved by the FDA in the following formulation(s):

SUTENT (sunitinib malate - capsule; oral)

• 
  Manufacturer: CPPI CV
  
  Approval date: January 26, 2006
  
  Strength(s): EQ 12.5MG BASE, EQ 25MG BASE, EQ 50MG BASE ^[RLD]


• 
  Manufacturer: CPPI CV
  
  Approval date: March 31, 2009
  
  Strength(s): EQ 37.5MG BASE
  

Has a generic version of Sutent been approved?

No. There is currently no therapeutically equivalent version of Sutent available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sutent. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pyrrole substituted 2-indolinone protein kinase inhibitors
  Patent 6,573,293
  Issued: June 3, 2003
  Inventor(s): Peng Cho; Tang & Todd A.; Miller & Xiaoyuan; Li & Li; Sun & Chung Chen; Wei & Shahrzad; Shirazian & Congxin; Liang & Tomas; Vojkovsky & Asaad S.; Nematalla & Michael; Hawley
  Assignee(s): Sugen, Inc.
  Pharmacia & Upjohn Co.
  The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
  
  Patent expiration dates:
  
  
  • February 15, 2021
    
    ✓ 
    Patent use: TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Pyrrole substituted 2-indolinone protein kinase inhibitors
  Patent 7,125,905
  Issued: October 24, 2006
  Inventor(s): Tang; Peng Cho & Miller; Todd A. & Li; Xiaoyuan & Sun; Li & Wei; Chung Chen & Shirazian; Shahrzad & Liang; Congxin & Vojkovsky; Tomas & Nematalla; Asaad S. & Hawley; Michael
  Assignee(s): Agouron Pharmaceuticals, Inc.
  The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
  
  Patent expiration dates:
  
  
  • February 15, 2021
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
  Patent 7,211,600
  Issued: May 1, 2007
  Inventor(s): Lipson; Ken & McMahon; Gerald
  Assignee(s): Sugen Inc.
  The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
  
  Patent expiration dates:
  
  
  • December 22, 2020
    
    ✓ 
    Patent use: TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 26, 2011 - NEW CHEMICAL ENTITY
  
  
  • May 20, 2014 - TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
  
  

See also...

• Sutent Consumer Information (Wolters Kluwer)
• Sutent Consumer Information (Cerner Multum)
• Sutent Advanced Consumer Information (Micromedex)
• Sutent AHFS DI Monographs (ASHP)
• Sunitinib Consumer Information (Wolters Kluwer)
• Sunitinib Consumer Information (Cerner Multum)
• Sunitinib Advanced Consumer Information (Micromedex)
• Sunitinib malate Advanced Consumer Information (Micromedex)
• Sunitinib Malate AHFS DI Monographs (ASHP)

Prodepres

Prodepres may be available in the countries listed below.

Ingredient matches for Prodepres

Sertraline

Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Prodepres in the following countries:

• Dominican Republic

International Drug Name Search

Retilon

Retilon may be available in the countries listed below.

Ingredient matches for Retilon

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Retilon in the following countries:

• Ethiopia

International Drug Name Search

Pladogrel

Pladogrel may be available in the countries listed below.

Ingredient matches for Pladogrel

Clopidogrel

Clopidogrel is reported as an ingredient of Pladogrel in the following countries:

• Indonesia

International Drug Name Search

Pemix

Pemix may be available in the countries listed below.

Ingredient matches for Pemix

Cinitapride

Cinitapride tartrate (a derivative of Cinitapride) is reported as an ingredient of Pemix in the following countries:

• Mexico

International Drug Name Search